AI assistant
Emergent BioSolutions Inc. — Director's Dealing 2020
Feb 14, 2020
32870_dirs_2020-02-13_6b5002c4-e421-4157-be6e-720774f862a6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2020-02-05
Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-05 | Common Stock | M | 20000 | $25.62 | Acquired | 1499018 | Direct |
| 2020-02-05 | Common Stock | M | 20000 | $25.62 | Acquired | 1519018 | Direct |
| 2020-02-05 | Common Stock | M | 8316 | $25.62 | Acquired | 1479018 | Direct |
| 2020-02-06 | Common Stock | M | 11684 | $25.62 | Acquired | 1479018 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-05 | Employee Stock Options (Right to Buy) | $25.62 | M | 20000 | Disposed | 2021-03-10 | Common Stock (20000) | Direct |
| 2020-02-05 | Employee Stock Options (Right to Buy) | $25.62 | M | 20000 | Disposed | 2021-03-10 | Common Stock (20000) | Direct |
| 2020-02-05 | Employee Stock Options (Right to Buy) | $25.62 | M | 8316 | Disposed | 2021-03-10 | Common Stock (8316) | Direct |
| 2020-02-06 | Employee Stock Options (Right to Buy) | $25.62 | M | 11684 | Disposed | 2021-03-10 | Common Stock (11684) | Direct |
Footnotes
F1: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934.
F2: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises.
F3: The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sale of Common Stock by the Reporting Person as reported on the Form 4 filed by the Reporting Person with the SEC on February 7, 2020.
F4: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017.